ArticleScientific reports2026
Neuropeptide Y drives vitiligo progression via NPYR-mediated NF-κB activation: a novel therapeutic target.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Neuropeptide Y (NPY) is a neurotransmitter involved in stress response and immune modulation and its dysregulation may contribute to the pathogenesis of vitiligo by influencing melanocyte function and autoimmune responses. This study aimed to explore the role and molecular mechanism of NPY in the progression of vitiligo. In vitro, human immortalized keratinocyte (HaCaT) cells were treated with H2O2 to simulate oxidative stress conditions observed in vitiligo. Through specific knockdown of the NPY receptor (NPY2R or NPY4R) achieved by siRNA transfection, combined with techniques such as Western blot (WB), ELISA and RT-qPCR, we found that NPY primarily activated the NF-κB signaling pathway via the NPY2R, thereby inducing the expression of key inflammatory cytokines, including CXCL9, CXCL10, and IL-15. Concurrently, NPY reduced intracellular ROS levels and partially inhibited H2O2-induced keratinocyte apoptosis. In vivo, a H2O2-induced vitiligo mouse model revealed that NPY exacerbated skin depigmentation, promoted NF-κB activation, increased expression of IL-15, and enhanced CD8 + T cell infiltration. In contrast, NPY2R inhibitors effectively reversed these phenotypes. Further assays indicated that NPY treatment decreased MDA content in skin tissue while elevating the activities of SOD and GSH-Px. Moreover, TUNEL staining and WB analysis of cleaved caspase-3 demonstrated that NPY could inhibit melanocyte apoptosis. Overall, this study was the first to demonstrate that NPY promoted the expression of CXCL9, CXCL10, and IL-15 by activating the NPY2R-mediated NF-κB signaling pathway in keratinocytes, thereby synergizing with oxidative stress to recruit CD8 + T cells and drive vitiligo progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.